Jakarta, CNN Indonesia –
Indonesian Association of Internal Medicine Specialists (Papdi) appealed to the program vaccination not rushed just to pursue positive case targeting targets.
Papdi considered that serious efforts were needed to ensure the feasibility and safety of vaccines. The security referred to is the absence of post-immunization follow-up events (AEFI) or serious and serious side effects.
“If developing a vaccine means there are stages, ideally the vaccine can be used until it is safe and can be used for up to five years of phase I-III research to post marketing surveillance, so we believe it is safe,” said Papdi Chairman Sally A Nasution when contacted by CNNIndonesia.com, Wednesday ( 21/10).
Apart from safety, Sally also asked the government to pay attention to the effectiveness of vaccines. According to him, vaccines which cost a lot of money must really know the function of their use. According to him, this must be emphasized by the government so that the public is convinced.
Sally admitted that she received many questions from the wider community, patients, and colleagues who were concerned about the effectiveness of the vaccine against the corona virus.
Apart from that, Papdi’s question was in response to the government’s plan which claims to be vaccinated soon. The government admits that the vaccines that Indonesia will buy from several countries will come next month, including Cansino, G42 or Sinopharm, and Sinovac.
“From the public, doctors question that. Because doctors are the main target of vaccination, and later on giving vaccines, we have two responsibilities,” he explained.
Sally admitted that her party will continue to oversee the clinical process of vaccine procurement, from the results of phase three clinical trials to see side effects.
Responding to the potential decision made by BPOM in issuing an Emergency Use Authorization (EUA) for the three vaccine products that will be carried out in Indonesia. Sally also admitted that BPOM had issued EUA of a type of medicine to her.
However, according to him, drugs are different from vaccines, especially a vaccine that has just been developed to ward off a new type of virus.
“EUA is temporary. There is time until there is a drug that is proven to be more patentable for therapy. Now, for the vaccine, we discussed yesterday whether it is safe because this is something new, if the drug is a bit different, we know its old drug,” he said.
However, Sally admits that he still appreciates the government’s efforts to provide a vaccine as a way to get rid of the country from this pandemic. According to him, the government has taken a step better in fighting for the procurement of vaccines which are also being fought over by other nations.
“We really appreciate the government who has been looking for it to import vaccines so they don’t miss it,” he concluded.
Previously, the government revealed its plan to vaccinate the Covid-19 vaccine in November 2020. The plan came after the government imported a number of vaccines from foreign companies, such as Cansino, G42 or Sinopharm, and Sinovac.
In detail, Cansino has undertaken 100 thousand vaccine doses (single dose) in November 2020 and around 15-20 million for 2021. Then, Sinopharm undertakes 15 million doses of vaccine (dual dose) this year. Of these, as many as 5 million doses began arriving in November 2020. Meanwhile, Sinovac has committed to 3 million doses of vaccine by the end of December 2020.
Currently, the vaccines from these three companies are in the final stages of phase 3 clinical trials. In detail, Cansino conducted the 3rd stage of clinical trials in China, Saudi Arabia, Russia and Pakistan. Then, Sinopharm conducted the 3rd phase of clinical trials in China, United Arab Emirates (UAE), Peru, Morocco and Argentina. Meanwhile, Sinovac is conducting phase 3 clinical trials in China, Indonesia, Brazil, Turkey, Bangladesh and Chile.
(khr/ain)
– .
